Change to Yellow Card reporting in children

The MHRA no longer requires all suspected adverse drug reactions (ADRs) in children and adolescents to be reported.

The quickest ADR reporting method is online but a paper copy of the Yellow Card form can alternatively be posted to the MHRA. | SCIENCE PHOTO LIBRARY
The quickest ADR reporting method is online but a paper copy of the Yellow Card form can alternatively be posted to the MHRA. | SCIENCE PHOTO LIBRARY

This change has been made in response to feedback that mandatory reporting of all suspected ADRs in children was impractical and deterred reporting. The advice for reporting adverse reactions is now the same for adults and children.

When to report

A Yellow Card needs to be completed for any ADR that is:

  • serious or results in harm and/or
  • associated with newer drugs and vaccines identified by the black triangle symbol (▼).

A serious reaction is one that is fatal, life-threatening, disabling or incapacitating, causes a congenital abnormality or results in hospitalisation, or is medically significant for any other reason.

ADRs meeting the above criteria should be reported if they are suspected to be caused by medicines, vaccines, herbal or complementary products, including from misuse or overdose, or from use of unlicensed or off-label medicines.

Where harm occurs as a result of a medication error, a Yellow Card may be completed or the error can be reported via the National Reporting and Learning System.

A paper copy of the Yellow Card form can be found at the back of the print issue of MIMS. This will be updated for the next quarterly edition (December) to reflect the changes to reporting ADRs in children and adolescents.

Further information: MHRA Drug Safety Update, September 2014

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Vitamin D3 Supplements

Formulations and indications of colecalciferol preparations.

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Treatment with febuxostat (Adenuric) should be avoided...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Colestid Orange. Use our constantly updated...

Updated bowel disease treatment summaries published by MIMS

Updated bowel disease treatment summaries published by MIMS

Updated quick-reference summaries of the latest NICE...